Spectrum Pharmaceuticals, Inc., SPPI - Spectrum Pharmaceuticals have completely acquired patent rights for Renazorb(TM) and Renalan(TM)
Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc. have completely acquired all the patent rights that is associated with Renazorb(TM) and Renalan(TM) from Altair Nanotechnologies, Inc. Both the companies are based in the US.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
This agreement amends and restates an existing, limited licensing agreement between Spectrum and Altair, for Renazorb(TM) and Renalan(TM) compound. Spectrum will now have exclusive worldwide rights to Renazorb(TM), Renalan(TM), and any related compounds in any field of use.
StockEinstein.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
Thank you for your interest in Findit News. A member of the Findit News team will contact you soon to show you how you can take your marketing to the next level with press releases on Findit.
